CHRS.NASDAQCoherus Biosciences, INC

Form 4: Coherus BioSciences Director Acquires 112,000 Stock Options

Sentiment:

SEC Form 4 Filing

📋All filings for Coherus Biosciences, INC
🔒Login to Follow

Mark Stolper, a director at Coherus BioSciences, acquired 112,000 stock options on June 3, 2024, exercisable after one year.

Summary

  • Mark Stolper, a director of Coherus BioSciences, Inc. (CHRS), filed a Form 4 to report changes in beneficial ownership.
  • On June 3, 2024, Stolper acquired 112,000 stock options with an exercise price of $1.76.
  • These options vest and become exercisable on June 3, 2025, contingent upon Stolper's continued service with Coherus BioSciences.
  • The options expire on June 3, 2034.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

  • The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term performance.

Key Dates

DateDescription
06/03/2024Date of transaction: Mark Stolper acquired 112,000 stock options.
06/03/2025Vesting date: 100% of the options vest, subject to continued service.
06/03/2034Expiration date: The stock options expire.
06/05/2024Date of Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.